*The MiniMedTM 780G pump and new CGM are under FDA review and not currently for sale in the U.S
Many key advancements have occurred in diabetes research over the past 100 years. See how Medtronic has helped pioneer many of the "firsts" that have transformed diabetes care.LEARN MORE
Refers to SmartGuard? Auto Mode. Some user interaction required. Individual results may vary.
Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.
The MiniMed? 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed? 770G system includes SmartGuard? technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed? 770G system consists of the following devices: MiniMed? 770G insulin pump, the Guardian? Link (3) transmitter, the Guardian? Sensor (3), one-press serter, the Accu-Chek? Guide Link blood glucose meter, and the Accu-Chek? Guide test strips. The system requires a prescription.
The Guardian? Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian? Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek? Guide Link blood glucose meter and not on values provided by the Guardian? Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek? Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the MiniMed? 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed? 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed? 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
Important Safety Information: Guardian? Connect CGM System
The Guardian? Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.
IMPORTANT SAFETY INFORMATION FOR INPEN? SMART INSULIN PEN:
The InPenTM requires a prescription. It is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin. The pen injector is compatible with Lilly Humalog? U-100 3.0 mL cartridges, Novo Nordisk Novolog? U-100 3.0 mL cartridg- es, and Novo Nordisk Fiasp? U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.
The InPenTM dose calculator, a component of the InPenTM app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a pa- tient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data.
For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-speci?c target blood glucose, insulin-to-carbohydrate ratio, insulin sensitivity pa- rameters, and duration of insulin action to be programmed into the software prior to use as it is required for set up.
For an insulin dose based on ?xed/variable meal sizes, a healthcare professional must provide patient-speci?c ?xed doses/meal sizes to be programmed into the software prior to use.
For additional product and important safety considerations, see User Guide and http://bit.ly/InPenSafety.
IMPORTANT SAFETY INFORMATION: i-PORT ADVANCE? INJECTION PORT
i-Port AdvanceTM injection port is prescription-indicated for patients who administer, or to whom is administered, multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple drug injections without the discomfort of additional needle sticks. Site infection and/or irritation is a risk. Patients experiencing such symptoms should immediately consult their healthcare provider and/ or discontinue use. For complete details, please consult i-Port AdvanceTM product user guide.